The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 17, 2020

Filed:

Jul. 05, 2018
Applicant:

Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);

Inventors:

Zhen Li, Monona, WI (US);

Rui Zhu, Middleton, WI (US);

Tao Pei, Middleton, WI (US);

Anthony Nicholas, Oregon, WI (US);

Erik W Bush, Verona, WI (US);

Assignee:

Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61P 5/40 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61P 5/40 (2018.01); C12N 15/1138 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/333 (2013.01); C12N 2310/335 (2013.01); C12N 2310/343 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2320/32 (2013.01);
Abstract

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene. The alpha-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an alpha-ENaC gene. Pharmaceutical compositions that include one or more alpha-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described alpha-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells, in vivo, provides for inhibition of alpha-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects.


Find Patent Forward Citations

Loading…